What is Carticel and is it right for my patient?
An overview (and inside view).
Carticel is an autologous cellular product indicated for:
- The repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea) caused by acute or repetitive trauma
- Patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure (e.g., debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft).
Manufactured by Vericel in an FDA-licensed and regulated facility, Carticel:
- Is created from a patient’s own chondrocytes
- Has been shown to decrease pain and increase function in a patient who failed a prior procedure.
- Has demonstrated durability up to 4 years (the duration of the STAR study) in a challenging patient population
- Is able to create a repair tissue with biological characteristics like those of hyaline cartilage
The world’s first cellular product in orthopedics, Carticel has been in commercial use by surgeons since 1995.
In 1997, the FDA granted a Biologic License for Carticel.
In 2007, the results of the Study of the Treatment of Articular Repair (STAR) were published. STAR was a post-approval, controlled, prospective study designed to determine the safety and efficacy of Carticel in patients who had an inadequate response to a prior surgical repair procedure.